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Measures of response in clinical trials of systemic sclerosis: the
combined response index for systemic sclerosis (CRISS) and
Outcome Measures in Pulmonary Arterial Hypertension related
to Systemic Sclerosis (EPOSS)
Abstract
There have been steady efforts to develop a combined response index for systemic sclerosis (CRISS). A
parallel and equally successful effort has been made by an Expert Panel on Outcome Measures in PAH
related to Systemic Sclerosis (EPOSS) to measure effect in treatment of pulmonary arterial hypertension
of systemic sclerosis (PAH-SSc). CRISS conducted a Delphi process combined with expert review to
identify 11 candidate domains for inclusion in a core set of outcomes for SSc clinical trials: soluble
biomarkers, cardiac, digital ulcers, gastrointestinal, global health, health related quality of life (HRQOL)
and function, musculoskeletal, pulmonary, Raynaud's, renal, and skin. Tools within domains were also
agreed upon. Concentrating on one aspect of disease, PAH, EPOSS also conducted a Delphi process and
judged the following domains as the most appropriate for randomized controlled trials in PAH-SSc: lung
vascular/pulmonary arterial pressure, cardiac function, exercise testing; severity of dyspnea,
discontinuation of treatment; quality of life/activities of daily living; global state; and survival. Possible
useful tools within each domain were also agreed on. Patient derived, physician derived, and objective
measures of response will be included and combined with the idea that each reflects different aspects of
PAH (EPOSS) and overall disease (CRISS) although this assumption may not prove true and can be
separated if statistically and clinically valid to do so. In either case, prospective studies will require
measurement of all domains, and tools are required and will be developed to define appropriate
combined measures of response. CRISS and EPOSS are being developed through the OMERACT
process. Through Delphi process and literature review significant progress has been made for both
indices, and prospective data are being collected.
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ABSTRACT 
Introduction. There have been steady efforts to develop a Combined Response Index for 
Systemic Sclerosis (CRISS).  A parallel, and equally successful, effort has occurred 
regarding measurement of effect in the treatment of the pulmonary arterial hypertension 
of systemic sclerosis (SSC PAH), called EPOSS -Expert Panel on Outcome Measures in 
PAH related to Systemic Sclerosis.  
Results. For CRISS a Delphi process combined with expert review resulted in 11 
candidate domains for inclusion in a core set of outcomes for SSc clinical trials.  These 
domains are soluble biomarkers, cardiac, digital ulcers, gastro-intestinal, global health, 
health related quality of life and function, musculoskeletal, pulmonary, Raynaud’s, renal 
and skin. Tools within domains were also agreed upon.  
 EPOSS concentrated on one aspect of the disease, PAH.  Using a Delphi 
process, the following domains were judged as most appropriate for randomised 
controlled trials in PAH-SSC: lung vascular/pulmonary arterial pressure, cardiac function, 
exercise testing; severity of dyspnea, discontinuation of treatment; quality of life/activities 
of daily living; global state; and survival. Possible useful tools within each domain were 
also agreed upon.  
 Patient derived, Physician derived and objective measures of response will be 
included and combined with the idea that each reflects different aspects of PAH(EPOSS) 
and overall disease (CRISS), although  this may not prove true and can be considered 
for separation if statistically and clinically valid to do so.   
Plans. In both cases, prospective studies to include measurement of all domains and 
tools are required and are being undertaken to define appropriate combined measures 
of response 
Conclusion. An overall combined measures of response in systemic sclerosis 
(CRISS) and a combined measure of response for PAH-SSC (EPOSS) are being 
developed through the OMERACT process.  Significant progress has been made using 
the Delphi process and literature review for both indices and prospective data are being 
collected. 
 
INTRODUCTION 
 
Since the last OMERACT, 2006, there have been steady efforts to develop a 
measurement of effect for the treatment of the Pulmonary Arterial Hypertension of 
Systemic Sclerosis (PAH-SSc), within the OMERACT philosophy1.  This effort, called the 
Expert Panel on Outcome Measures in PAH related to Systemic Sclerosis (EPOSS), has 
made significant strides. A parallel effort to develop a Combined Response Index for 
Systemic Sclerosis (CRISS) has been ongoing and this effort is also progressing nicely.  
 Regarding EPOSS, there is need for a structured approach to define endpoints 
for PAH/SSc which take into account the methodological problems associated with 
possible SSc-specific confounding factors (e.g., musculoskeletal problems, joint 
contractures, fatigue and deconditioning, which may affect cardiopulmonary testing). 
  PAH is the major life expectancy limiting and debilitating complication of systemic 
sclerosis, affecting up to 20% of patients2. Right heart catheterisation (RHC) is the gold 
standard for diagnosis of PAH, but is underused because of the limited availability, 
complexity, invasiveness, and economic implications of the procedure3. Further, RHC-
derived hemodynamic parameters are useful for PAH diagnosis, but do not correlate well 
with either clinical outcomes or survival. Alternative endpoints are needed for clinical 
studies. Such endpoints will need to encompass a wide variety of domains (such as 
cardiac function, quality of life, lung function, soluble biomarkers) and tools 
(echocardiography, quality of life instruments such as SF-36).  
 Together with the CRISS effort (see below), the EPOSS work will develop a set 
of domains and tools specific for PAH-SSc. These are, in fact, complementary rather 
than combined efforts, although many of the same techniques and analyses apply to 
both the CRISS and EPOSS, thus justifying close, cooperative and synergistic efforts.   
 There has been substantial progress over the past decade in the development 
and validation of outcome measures and refinement of trial methodology in SSc4,5,6. This 
progress has been paralleled by an increased understanding of the pathogenesis of SSc 
and development of targeted therapies7,8,9. The modified Rodnan skin score, a measure 
of skin thickness, has been used as the primary outcome measure in clinical trials of 
diffuse cutaneous SSc (called diffuse SSc or dcSSc from here on)10,11. However, the 
complexity and heterogeneity of the disease mandates a composite response measure 
that will capture differing organ involvements and patient-reported outcomes. Well-
validated, widely accepted combined response indices are more likely to be responsive 
to change than individual measures12,13, will facilitate drug development and improve 
assessment of efficacy of therapeutic agents12,14.   
 A CRISS for use in clinical trials of patients with diffuse SSc could facilitate the 
interpretation of results from clinical trials, similar to the American College of 
Rheumatology (ACR) response criteria and the Disease Activity Score definitions for 
rheumatoid arthritis. Rather than using numerous outcomes that vary from trial to trial, a 
core set of outcomes will produce a single efficacy measure. 
 This article will outline the progress and plans for the EPOSS and CRISS 
initiatives. 
 
Results and Plans 
A. EPOSS (Expert Panel on Outcome Measures in PAH related to Systemic Sclerosis) 
Progress to Date: 
The EPOSS group first published an article defining the need for improved outcome 
measures in pulmonary arterial hypertension related to systemic sclerosis (PAH-SSC)15.   
Using a Delphi process, a series of domains and tools were developed which 
might be used as alternative endpoints to the use of the right heart catheterisation (RHC) 
to define PAH-SSc, as repeated RHC are difficult to accomplish in clinical trials. 
The results of the EPOSS Delphi process have been published in Arthritis and 
Rheumatism/Arthritis Care & Research16: 69 PAH- SSc experts, including 
rheumatologists, cardiologists, and pulmonologists rated a list of domains and 
measurement tools in an Internet-based Delphi consensus study.  A statistical cluster 
analysis was used to define the specific domains and tools to be included in this 
preliminary measurement tool. This was followed by a meeting of the EPOSS Steering 
Committee to remove redundant items, inconsistencies and to omit elements not 
feasible in clinical trials as well as to make other judgments on a clinical basis.  The 
following domains and tools were judged as most appropriate for randomised, controlled 
trials in PAH-SSc: lung vascular/pulmonary arterial pressure and cardiac function both 
measured by right heart catheterisation and echocardiogram, six minute walk test, 
oxygen saturation exercise; severity of dyspnea on a visual analogue scale; 
discontinuation of treatment as measured by serious adverse events; quality of 
life/activities of daily living measured by the Short Form 36 and Health Assessment 
Questionnaire Disability Index; global state assessed by physician measures and 
survival (Table 1). 
 An additional analysis examined the differences in responses between 
pulmonologists and cardiologists compared to rheumatologists17.  In general, it was 
found that rheumatologists favoured patient-derived questionnaires more frequently than 
cardiologists/pulmonologists while the latter favoured specific pulmonary related 
measures of response, but that a combination of results encompassing both groups’ 
assessments are required for full description and measurement of PSH-SSc 
 Preparatory to a prospective study and/or use of existing data to validate the 
domains and tools outlined above, an in depth structured literature review has been 
undertaken for echocardiography and for the six minute walk test (both accepted as 
posters and presented at the 2008 EULAR meeting). The structured literature review will 
show which parts of the selected outcome measures have already been sufficiently 
validated in PAH-SSc according to the OMERACT filter to require no more research. 
More importantly, it will define those measures that need further validation before those 
measures can be used to assess PAH-SSc. 
 
Plans: 
For the EPOSS effort, we are presently: 
1. Completing the systematic literature review on core set outcomes defined by the 
Delphi study  
 
2. Planning to validate the domains and tools as chosen through the Delphi exercise 
 
(a) We plan to obtain data from completed clinical trials which include as many 
as possible of the chosen domains/ tools in order to corroborate and winnow the 
tools which will be used in future clinical trials.  
(b) Based on the results of the systematic literature review, the remaining 
aspects of the core set measures, which have been identified as being not yet 
fully validated, will be assessed in further validation studies. Fortunately, a large 
number of randomised controlled trials in PAH have recently been performed. A 
sub-analysis on PAH-SSc patients from the placebo arms of these studies will be 
performed and we are attempting to get these data at present. 
 
3.  Developing a patient Delphi exercise 
From the patients’ perspective, changes in functional ability may be more distressing 
and debilitating than changes in objective measures of disease that are often used by 
physicians. However, there is insufficient information regarding which domains may be 
most important to patients, because many outcome measures used in PAH/SSc report 
either generic QOL, or single domains (e.g., physical function) or are not measured (e.g., 
fatigue).  
(a) We will evaluate patients’ assessment of the disease and symptom burden in 
PH/SSc using patient-centered qualitative methods. This adds an important 
component to the core set defined by physicians outlined above. We will 
conduct focus groups and interviews of PH/SSc patients in order to determine 
patients’ perceptions of disease activity, disability, and HRQOL and to identify 
areas most distressful and concerning to patients. 
 
4.  The physician derived and objective measures of response will be developed 
separately from the patient derived measures. When completed, these two approaches 
to PAH/SSc will be examined in combination and separately to ascertain which approach 
is more sensitive to change in clinical trials, as they probably describe somewhat 
different aspects of PAH/SSc, thus improving the combined discriminating ability of a 
combined measure. On the other hand, there is no reason to insist on their combination 
in all circumstances and they may/should be used separately when it is appropriate. 
Further, if their combination does not enhance the discriminating ability of the combined 
measure, or if one or the other, by themselves, are better discriminators of response, 
this , too, will be ascertained. 
 
B. CRISS (Combined Response Index for Systemic Sclerosis) 
 
Progress to date: 
  
The first step in developing a Combined Response Index in Systemic Sclerosis 
(CRISS) was taken by conducting a structured Delphi exercise with participation 
of the Scleroderma Clinical Trial Consortium membership, to develop a 
provisional core set of items for clinical trials18.  In this exercise, 50 investigators 
provided 212 unique items for 11 domains in a one-year clinical trial of SSc 
patients.  In this trial 92% of the original investigators responded in the second 
round and rated 177 items.  Nominal group technique examined these data for 
consistency, redundancy, feasibility and validity, judging 31 of the items from the 
11 domains to be appropriate for inclusion in a one-year multicentre clinical trial.  
Thereafter, in a modified third round, the investigators ranked 30 of the 31 items 
as acceptable for inclusion in the course. The final domains chosen were (need 
these from the article) (Table 2).  An additional 14 items were included in a 
research agenda.  (Table 3) Dan: we will need ARD approval for these tables if 
we copy them  
 Recruiting for the one-year prospective cohort study, including the 
obtaining of data in all domains and by all tools suggested from the CRISS 
Delphi exercise, has begun.  To date, approximately 70 patients have been 
recruited into the trial. 
 
Plans: 
 
Preliminary efforts to develop a CRISS have included the pooling of data, 
comprising 635 diffuse SSc patients, from previously completed clinical trials of 
diffuse SSc to test some individual aspects of a possible combined index. 
Unfortunately, the 635-patient data-set lacks a number of the core set items 
chosen in the recent Delphi exercise, making that data-set unsuitable to 
completely test the proposed CRISS. Therefore, we are assessing all of the 
proposed core set items in a 1-year longitudinal observational study (see above) 
and will then employ a prospective, data-driven, consensus building technique to 
develop and quantitatively evaluate candidate definitions for a CRISS that will 
capture different organ involvements and patient-reported outcomes. 
 
For the CRISS effort, we are presently: 
1. Performing a prospective longitudinal observational clinical study to 
define a reliable, valid and responsive set of diffuse SSc measures for 
a CRISS, based on a recently completed Delphi exercise.  
a) We are collecting the data specified in the recently selected, 
Delphi-exercise-defined, core set in a 1-year observational 
study in 200 patients with early diffuse SSc (defined as ≤ 5 
years duration) at 4 academic Scleroderma Centers.  To date 
approximately 70 patients have been recruited into this 
observational cohort.  
b) We will assess the reliability, validity and responsiveness of the 
core set items from the real patient data collected in the 1-year 
observational study. 
c) We will revise and define a final core set based on the results 
obtained from Specific Aim 1b.  
d) The same considerations as for EPOSS will be true for the 
patient-derived aspects of the CRISS, as the potential tools in 
the CRISS include a number of patient-derived outcomes (e.g., 
SF-36, HAQ-DI, pain, global evaluations, and dyspnea). These 
will be considered in the same manner as for EPOSS, although 
for the present no separate evaluation by patients is planned. 
Nevertheless, the multiple patient-derived measures can be 
examined as a separate group within the CRISS, if separating 
those aspects from their underlying instruments is statistically 
and clinically valid.   
2. Employing prospective, data-driven, consensus building techniques to 
develop and quantitatively evaluate candidate definitions for an SSc-
CRI for diffuse SSc.   
a) We will create paper-patient profiles from the data gathered as 
part of 1c, above, from diffuse SSc patients over a 1-year time 
period. 
                      b) Using consensus formation techniques (Nominal Group 
Technique, we will have key-opinion leaders in the field rate 
paper-patient profiles in order to estimate validity characteristics 
of each candidate definition for a SSc-CRI. 
    We are planning a sample size of 200 patients to be 
able to select patient profiles plus anticipated dropouts  
c) We will use the ratings of the key-opinion leaders as the gold 
standard to estimate validity characteristics, such as sensitivity 
and specificity, we will compare each using area under the 
curve and receiver operating characteristics analyses. 
d) We will select a definition of CRISS for use in clinical trials in 
diffuse SSc that has high statistical discriminatory power and is 
most credible (highest face validity). 
      In SSc, the multiple organ system involvements can 
be either reversible or irreversible and the measures to separate 
these two aspects of SSc are not available. Rather the process 
of choosing the tools within the domains will be utilised to 
choose tools which are most sensitive to change. This, by 
implication, assumes those tools reflect reversible aspects of 
SSc, although this is clearly an empiric rather than physiologic 
or pathologically based decision 
      By grouping the patient derived measures, it may also 
be possible to find a patient oriented portion of the CRISS, 
which can be used separately or within the complete CRISS. 
However, should the patient derived measures prove to be an 
integral and required portion of the CRISS, when considering 
sensitivity to change and clinical relevance (as seen in 
American College of Rheumatology criteria for rheumatoid 
arthritis and juvenile idopathic arthritis), this finding will be 
specifically addressed when the final version of the CRISS has 
been completed.  
 
CONCLUSION  
 
An overall combined measures of response in systemic sclerosis (CRISS) and a 
combined measure of response for PAH-SSc (EPOSS) are being developed through the 
OMERACT process.  Significant progress has been made using the Delphi process and 
literature review for both indices and prospective data are being collected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Final Core set of Physician-Derived Domains and Measurement Tools 
for EPOSS, defined by the Delphi Survey*. 
Cardiac Function 
Right Heart Catheterisation 
Echocardiography 
Dyspnea Visual Analogue Scale 
Discontinuation of Treatment  
Adverse events 
Serious adverse events 
Dyspnea 
Dyspnea VAS 
Exercise Testing 
6-Minute Walk Test 
Oxygen saturation on exercise 
Global State of Physician 
Survival 
Lung Vascular 
Right Heart Catheterization 
Echocardiography 
Quality of Life 
Short-Form-36 Score 
Health Assessment Questionnaire Disability Index 
 
* Modified from Ref. 16 
 
 
 
 
 
 
Table 2. Core Set Items Selected for 11 Domains for the CRISS. 
Soluable Biomarkers 
Acute phase reactant(s) — Erythrocyte sedimentation rate and/or C-reactive protein 
Cardiac 
Cardiac Echocardiogram with doppler            
Right heart catheterisation 
6-Minute Walk Test* 
Borg Dyspnea Instrument * 
Digital Ulcers 
Active digital tip ulcer count on the volar surface 
Visual Analogue Scale digital ulcer (part of Scleroderma-Health Assessment Questionnaire-
Disability Index)  
Gastrointestinal 
Body mass index  
Validated gastrointestinal tract Visual Analogue Scale (37) or other SSc-Validated GI 
questionnaire 
Global Health 
Visual Analogue Scale/Likert patient global severity 
Visual Analogue Scale/Likert physician global severity 
Scleroderma-related health transition by patient 
Scleroderma-related health transition by physician¶ 
Health-Related Quality of Life and Function 
Health Assessment Questionnaire-Disability Index   
Visual Analogue Scale-pain scale from the HAQ-DI(51) 
Short Form –36 Score, version 2(52)                                                                                      
Musculoskeletal 
Tender Joint Count 
Tendon friction rubs assessed by the physician ¶ 
Serum creatinine phosphokinase, aldolase 
Pulmonary 
Pulmonary Function Testing 
Validated measure of Dyspnea 
Breathing Visual Analogue Scale from the Scleroderma Health Assessment Questionnaire (S-
HAQ)(37) 
High resolution computer tomography (HRCT) of the lungs: quantifiable scale*   
Raynaud’s Phenomenon 
Raynaud’s Condition Score(53) 
Visual Analogue Scale Raynaud's (part of S-HAQ) (37) 
Renal 
Calculated creatinine clearance based on serum creatinine (Cockroft-Gault or MDRD formula) 
Pre-defined renal crisis (Presence or absence) 
Skin 
Modified Rodnan Skin Score (Range 0-51) 
Visual analog scale or /Likert of patient global assessment for skin activity ¶ 
Visual Analogue Scale or /Likert of physician global assessment for skin activity ¶ 
Durometer    
 
Table modified from Ref. 18 
 
 Standardised central reading mechanism strongly encouraged, * if relevant to 
the study, ¶ Items were based on Steering Committee and SCTC consensus 
despite lack of full validation  
 
 
 
 
 
 
 
 
 
 
 
 Table 3. Proposed items for future research 
Research Agenda 
Biomarkers 
Markers of the collagen breakdown e.g., Soluble IL-2 receptor levels, Procollagen I and III 
aminopropeptide, connective tissue growth factor (CTGF) levels, Serum collagen I 
carboxyterminal telopeptide, urinary pyridinoline cross-link compounds of collagen, etc. 
Cardiac 
Serum Pro- brain natriuretic peptide (Pro-BNP) or NT-Pro-BNP  
Non invasive measures of cardiac function e.g., cardiac magnetic resonance imaging, tissue 
Doppler 
Digital Ulcers 
Development of digital ulcer condition score that captures activity, severity, and impact 
Gastrointestinal 
Scleroderma-Gastrointestinal 1.0 questionnaire(3) 
Gastric emptying time and/or 24-hour small bowel transit time 
Global Health 
Medsger Severity Index (27) 
Health-related Quality of Life and Function 
Measure of health utility e.g., SF-6D, EuroQol, Quality of Well Being Scale, time trade-off, 
standard gamble 
Measure of fatigue e.g., Functional assessment of chronic illness therapy (FACIT)-Fatigue 
Measure of depression/ anxiety e.g., Beck Depression Inventory, Center for Epidemiologic-
Depression Scale 
Musculoskeletal 
Large joint contracture 
Michigan Hand Questionnaire(18) 
Skin 
Measure of telangiectasia 
Visual analog scale or /Likert patient global assessment for pruritus 
 
Table modified from Ref. 18 
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